Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that the following documents have been sent to shareholders:
· Annual Report and Accounts for the year ended 31 December 2020
· Notice of Annual General Meeting 2021 and voting proxy form
In accordance with AIM Rule 26, these documents are also available to view on the Company’s website:
https://www.openorphan.com/investors/reports-and-presentations/year/2021.
The 2020 Annual Report, and the Notice of AGM, which includes details of voting by proxy, have been posted to shareholders who have not consented to receive electronic communications.
The AGM is scheduled to be held at 12 noon BST on 21 July 2021 at the offices of Arden Partners plc, 125 Old Broad St, London EC2N 1AR, and will consider the resolutions set out in the Notice of AGM.
In light of the UK Government’s response to the ongoing COVID-19 outbreak, the Company and the Executive Chairman have determined that the Resolutions to be proposed at the AGM shall be voted on through a poll rather than on a show of hands; and, accordingly, shareholders are strongly encouraged to either submit their Form of Proxy or use the CREST Proxy Voting Service, rather than attend the meeting in person.
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.
If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.
